Publikationen
Prof. Dr. med. Sven Roger Perner
Originalarbeiten:
Schäfer MH, Lingohr P, Sträßer A, Lehnen NC, Braun M, Perner S, Höller
T, Kristiansen G, Kalff JC, Gütgemann I.
Fibroblast growth factor receptor 1 gene amplification in gastric
adenocarcinoma.
Hum Pathol. 2015 Jun 23. [Epub ahead of print]
Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A,
Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N,
Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V,
Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun
M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M,
Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z,
Dolznig H, Kenner L.
STAT3 regulated ARF expression suppresses prostate cancer
metastasis.
Nat Commun. 2015 Jul 22;6:7736. doi: 10.1038/ncomms8736.
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X,
Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park
KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO,
Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer
B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C,
Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T,
Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V,
Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright
GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre
A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L,
Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J,
Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB,
Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M,
Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C,
Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage
J, Thomas RK.
Comprehensive genomic profiles of small cell lung cancer.
Nature. 2015 Jul 13. doi: 10.1038/nature14664. [Epub ahead of print]
Jakobs C, Perner S, Hornung V.
AIM2 Drives Joint Inflammation in a Self-DNA Triggered Model of
Chronic Polyarthritis.
PLoS One. 2015 Jun 26;10(6):e0131702.
Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M,
von Mässenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten
R, Boehm D, Vogel W, Kleczko EK, Eagles J, Hirsch FR, Van Bremen
T, Bootz F, Schröck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner
S.
FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-
dependent head and neck squamous cell cancers.
Clin Cancer Res. 2015 May 26. pii: clincanres.3357.2014. [Epub ahead
of print]
Gakis G, Todenhöfer T, Braun M, Fend F, Stenzl A, Perner S.
Immunohistochemical assessment of lymphatic and blood vessel
invasion in T1 urothelial carcinoma of the bladder.
Scand J Urol. 2015 Apr 28:1-6. [Epub ahead of print]
Shaikhibrahim Z, Anne Offermann A, Halbach R, Vogel W, Braun M,
Kristiansen G, Bootz F, Mikut R, Lengerke C, Reischl M, Schröck A,
Perner S.
Clinical and molecular implications of MED15 in Head and Neck
Squamous Cell Carcinoma
Am J Pathol., 2015 Apr;185(4):1114-22.
Blondeau JJC, Deng M, Syring I, Schrödter S, Schmidt D, Perner S,
Müller SC, Ellinger J.
Identification of novel long non-coding RNAs in clear cell renal cell
carcinoma.
Clin Epigenetics 2015, 7:10 doi:10.1186/s13148-015-0047-7
Sailer V, Khov Eberhard HL, Stephan C, Wernert N, Perner S, Jung K,
Dietel M, Bubendorf L, Kristiansen G.
Glutathione S-Transferase-Pi Protein expression in prostate cancer – not
always a useful diagnostic tool.
Histopathology. 2015 Feb 12. doi: 10.1111/his.12671. [Epub ahead of
print]
Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, MezaZepeda
LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T,
Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C,
Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright
GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sänger J, Brustugun
OT, Helland Å, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla
E, Vingron M, Perner S, Haas SA, Thomas RK.
Identification of novel fusion genes in lung cancer using breakpoint
assembly of transcriptome sequencing data.
Genome Biol. 2015 Jan 5;16(1):7.
Hartmann S, Döring C, Vucic E, Chan FC, Ennishi D, Tousseyn T, de
Wolf-Peeters C, Perner S, Wlodarska I, Steidl C, Gascoyne RD,
Hansmann ML.
Array comparative genomic hybridization reveals similarities between
nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte
rich large B cell lymphoma.
Br J Haematol. 2015 May;169(3):415-22.
Gallala H, Winter J, Veit N, Nowak M, Perner S, Courts C, Kraus D,
Janzen V, Probstmeier R.
Staurosporine analogs promote distinct patterns of process outgrowth and
polyploidy in small cell lung carcinoma cells.
Tumour Biol. 2015 Apr;36(4):2725-35.
Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn
AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz
BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C,
Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F.
Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic
response and drives lymphomagenesis.
Nat Med. 2014 Dec;20(12):1401-9.
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y,
Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen
R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J,
Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y,
Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH,
Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W.
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung
cancer.
Nat Med. 2014 Sep;20(9):1027-34.
Rüenauver K, Menon R, Svensson MA, Carlsson J, Vogel W, Andrén O,
Nowak M, Perner S.
Prognostic significance of YWHAZ expression in localized prostate
cancer.
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):310-4.
Heselmeyer-Haddad KM, Berroa Garcia LY, Bradley A, Hernandez L, Hu
Y, Habermann JK, Dumke C, Thorns C, Perner S, Pestova E, Burke C,
Chowdhury SA, Schwartz R, Schäffer AA, Paris PL, Ried T.
KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker
for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy.
Am J Pathol. 2014 Oct;184(10):2671-86.
Stein J, Majores M, Rohde M, Lim S, Schneider S, Krappe E, Ellinger J,
Dietel M, Stephan C, Jung K, Perner S, Kristiansen G, Kirfel J.
KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker
for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy.
Am J Pathol. 2014 Sep;184(9):2430-7.
Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK,
Bohm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit
JM, Perner S, Heasley LE.
Non-Amplified FGFR1 is a Growth Driver in Malignant Pleural
Mesothelioma.
Mol Cancer Res. 2014 Oct;12(10):1460-9.
Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M,
Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch C, Svensson M,
Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.
MED12 overexpression is a frequent event in castration-resistant prostate
cancer.
Endocr Relat Cancer. 2014 Aug;21(4):663-75
Queisser A, Hagedorn SA, Braun M, Vogel W, Duensing S, Perner S.
Comparison of different prostatic markers in lymph node and distant
metastases of prostate cancer.
Mod Pathol. 2015 Jan;28(1):138-45.
Wynes MW, Hinz TK, Gao D, Martini M, Marek L, Ware KE, Edwards MG,
Bohm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S,
Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR,
Heasley LE.
FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict
FGFR TKI Sensitivity Across All Lung Cancer Histologies.
Clin Cancer Res. 2014 Jun 15;20(12):3299-309.
Schröck A, Bode M, Göke FJ, Bareiss PM, Schairer R, Wang H, Franzen
A, Kirsten R, van Bremen T, Queisser A, Kristiansen G, Heasley L, Bootz
F, Lengerke C, Perner S.
Expression and role of the embryonic protein SOX2 in head and neck
squamous cell carcinoma.
Carcinogenesis. 2014 Jul;35(7):1636-42.
Menzel M, Meckbach D, Weide B, Toussaint NC, Schilbach K, Noor S,
Eigentler T, Ikenberg K, Busch C, Quintanilla-Martinez L, Kohlhofer U,
Göke A, Göke F, Handgretinger R, Ottmann C, Bastian BC, Garbe C,
Röcken M, Perner S, Kohlbacher O, Bauer J.
In melanoma, Hippo signaling is affected by copy number alterations and
YAP1 overexpression impairs patient survival.
Pigment Cell Melanoma Res. 2014 Jul;27(4):671-3.
Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidel D, Zander
T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G,
Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM,
Bogus M, Soltermann A, Brustugun OT, Helland A, Solberg S, LundIversen
M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z,
Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I,
Perner S, Lovly CM, Cappuzzo F, Travis WD, Wolf J, Vingron M,
Brambilla E, Haas SA, Buettner R, Thomas RK.
Frequent mutations in chromatin-remodelling genes in pulmonary
carcinoids.
Nat Commun. 2014 Mar 27;5:3518.
Brownstein CA, Beggs AH, Homer N, Merriman B, Yu TW, Flannery KC,
Dechene ET, Towne MC, Savage SK, Price EN, Holm IA, Luquette LJ,
Lyon E, Majzoub J, Neupert P, McCallie D Jr, Szolovits P, Willard HF,
Mendelsohn NJ, Temme R, Finkel RS, Yum SW, Medne L, Sunyaev SR,
Adzhubey I, Cassa CA, de Bakker PI, Duzkale H, Dworzy Ski P,
Fairbrother W, Francioli L, Funke BH, Giovanni MA, Handsaker RE, Lage
K, Lebo MS, Lek M, Leshchiner I, Macarthur DG, McLaughlin HM, Murray
MF, Pers TH, Polak PP, Raychaudhuri S, Rehm HL, Soemedi R, Stitziel
NO, Vestecka S, Supper J, Gugenmus C, Klocke B, Hahn A, Schubach
M, Menzel M, Biskup S, Freisinger P, Deng M, Braun M, Perner S, Smith
RJ, Andorf JL, Huang J, Ryckman K, Sheffield VC, Stone EM, Bair T,
Black-Ziegelbein EA, Braun TA, Darbro B, Deluca AP, Kolbe DL, Scheetz
TE, Shearer AE, Sompallae R, Wang K, Bassuk AG, Edens E, Mathews
K, Moore SA, Shchelochkov OA, Trapane P, Bossler A, Campbell CA,
Heusel JW, Kwitek A, Maga T, Panzer K, Wassink T, Van Daele D,
Azaiez H, Booth K, Meyer N, Segal MM, Williams MS, Tromp G, White P,
Corsmeier D, Fitzgerald-Butt S, Herman G, Lamb-Thrush D, McBride KL,
Newsom D, Pierson CR, Rakowsky AT, Maver A, Lovre I L, Palanda I A,
Peterlin B, Torkamani A, Wedell A, Huss M, Alexeyenko A, Lindvall JM,
Magnusson M, Nilsson D, Stranneheim H, Taylan F, Gilissen C, Hoischen
A, van Bon B, Yntema H, Nelen M, Zhang W, Sager J, Zhang L, Blair K,
Kural D, Cariaso M, Lennon GG, Javed A, Agrawal S, Ng PC, Sandhu
KS, Krishna S, Veeramachaneni V, Isakov O, Halperin E, Friedman E,
Shomron N, Glusman G, Roach JC, Caballero J, Cox HC, Mauldin D,
Ament SA, Rowen L, Richards DR, Lucas FA, Gonzalez-Garay ML,
Caskey CT, Bai Y, Huang Y, Fang F, Zhang Y, Wang Z, Barrera J,
Garcia-Lobo JM, González-Lamuño D, Llorca J, Rodriguez MC, Varela I,
Reese MG, De La Vega FM, Kiruluta E, Cargill M, Hart RK, Sorenson JM,
Lyon GJ, Stevenson DA, Bray BE, Moore BM, Eilbeck K, Yandell M, Zhao
H, Hou L, Chen X, Yan X, Chen M, Li C, Yang C, Gunel M, Li P, Kong Y,
Alexander AC, Albertyn ZI, Boycott KM, Bulman DE, Gordon PM, Innes
AM, Knoppers BM, Majewski J, Marshall CR, Parboosingh JS, Sawyer
SL, Samuels ME, Schwartzentruber J, Kohane IS, Margulies DM.
An international effort towards developing standards for best practices in
analysis, interpretation and reporting of clinical genome sequencing
results in the CLARITY Challenge.
Genome Biol. 2014 Mar 25;15(3):R53.
Klemm C, Dommisch H, Göke F, Kreppel M, Jepsen S, Rolf F, Dommisch
K, Perner S, Standop J.
Expression profiles for 14-3-3 zeta and CCL20 in pancreatic cancer and
chronic pancreatitis.
Pathol Res Pract. 2014 Jun;210(6):335-41.
Murmann T, Carrillo-García C, Veit N, Courts C, Glassmann A, Janzen V,
Madea B, Reinartz M, Harzen A, Nowak M, Perner S, Winter J,
Probstmeier R.
Staurosporine and extracellular matrix proteins mediate the conversion of
small cell lung carcinoma cells into a neuron-like phenotype.
PLoS One. 2014 Feb 28;9(2):e86910.
Boehm D, Vogel W, Franzen A, Schrock A, Bootz F, Heaseley LE, Braun
M, Perner S.
A new bright-field dual-colour chromogenic and silver in situ hybridization
method for the detection of FGFR1 gene copy number status.
Virchows Arch. 2014 May;464(5):547-51.
Matthaei H, Wu J, Dal Molin M, Shi C, Perner S, Kristiansen G, Lingohr P,
Kalff JC, Wolfgang CL, Kinzler KW, Vogelstein B, Maitra A, Hruban RH.
GNAS Sequencing Identifies IPMN-specific Mutations in a Subgroup of
Diminutive Pancreatic Cysts Referred to as „Incipient IPMNs“.
Am J Surg Pathol. 2014 Mar;38(3):360-3.
Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R,
Sollie T, Helenius G, Andersson SO, Demichelis F, Andrén O, Rubin MA.
A Comparative Study of ERG Status Assessment on DNA, mRNA, and
Protein Levels Using Unique Samples from a Swedish Biopsy Cohort.
Appl Immunohistochem Mol Morphol. 2014 Feb;22(2):136-41.
Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler TK,
Capper D, von Deimling A, Mittelbronn M, Perner S, Ikenberg K,
Hantschke M, Büttner P, Garbe C, Weide B.
Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437
Patients with Primary Melanoma.
PLoS One. 2014 Jan 24;9(1):e86194.
Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F,
Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel
W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z,
Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG,
Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM,
Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A,
Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron
M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas
SA, Yatabe Y, Thomas RK.
CD74-NRG1 fusions in lung adenocarcinoma.
Cancer Discov. 2014 Apr;4(4):415-22.
Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S,
Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S,
Bubendorf L, Ruiz C.
ERG rearrangement and protein expression in the progression to
castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31.
Shaikhibrahim Z, Menon R, Braun M, Offermann A, Queisser A, Boehm
D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O,
Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.
MED15, encoding a subunit of the mediator complex, is overexpressed at
high frequency in castration-resistant prostate cancer.
Int J Cancer. 2014 Jul 1;135(1):19-26.
Seidel D, Zander T, Heukamp LC, Peifer M, Bos M, Fernández-Cuesta L,
Leenders F, Lu X, Ansén S, Gardizi M, Nguyen C, Berg J, Russell P,
Wainer Z, Schildhaus HU, Rogers TM, Solomon B, Pao W, Carter SL,
Getz G, Hayes D, Wilkerson MD, Thunnissen E, Travis WD, Perner S,
Wright G, Brambilla E, Büttner R, Wolf J, Thomas RK, Gabler F,
Wilkening I, Müller C, Dahmen I, Menon R, König K, Albus K,
Merkelbach-Bruse S, Fassunke J, Schmitz K, Kuenstlinger H, Kleine MA,
Binot E, Querings S, Altmüller J, Bäßmann I, Nürnberg P, Schneider PM,
Bogus M, Büttner R, Perner S, Russell P, Thunnissen E, Travis WD,
Brambilla E, Soltermann A, Moch H, Brustugun OT, Solberg S, LundIversen
M, Helland Å, Muley T, Hoffmann H, Schnabel PA, Chen Y,
Groen H, Timens W, Sietsma H, Clement JH, Weder W, Sänger J,
Stoelben E, Ludwig C, Engel-Riedel W, Smit E, Heideman DA, Snijders
PJ, Nogova L, Sos ML, Mattonet C, Töpelt K, Scheffler M, Goekkurt E,
Kappes R, Krüger S, Kambartel K, Behringer D, Schulte W, Galetke W,
Randerath W, Heldwein M, Schlesinger A, Serke M, Hekmat K, Frank KF,
Schnell R, Reiser M, Hünerlitürkoglu AN, Schmitz S, Meffert L, Ko YD,
Litt-Lampe M, Gerigk U, Fricke R, Besse B, Brambilla C, Lantuejoul S,
Lorimier P, Moro-Sibilot D, Cappuzzo F, Ligorio C, Damiani S, Field JK,
Hyde R, Validire P, Girard P, Muscarella LA, Fazio VM, Hallek M, Soria
JC, Carter SL, Getz G, Hayes D, Wilkerson MD, Achter V, Lang U, Seidel
D, Zander T, Heukamp LC, Peifer M, Bos M, Pao W, Travis WD,
Brambilla E, Büttner R, Wolf J, Thomas RK, Büttner R, Wolf J, Thomas
RK.
A genomics-based classification of human lung tumors.
Sci Transl Med. 2013 Oct 30;5(209):209ra153.
Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R,
Böhm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W,
Heasley L, Buettner R, Perner S.
Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in
Colorectal Cancer.
Digestion. 2013 Oct 17;88(3):172-181.
Menon R, Deng M, Rüenauver K, Queisser A, Offermann A, Boehm D,
Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann
N, Biskup S, Rubin MA, Shaikhibrahim Z, Perner S.
Somatic copy number alterations by whole exome sequencing implicates
YWHAZ and PTK2 in castration-resistant prostate cancer.
J Pathol. 2013 Dec;231(4):505-16.
Weiss VL, Braun M, Perner S, Harz A, Vorreuther R, Kristiansen G,
Müller SC, Ellinger J. Prognostic significance of tumor thrombus
consistency in patients with renal cell carcinoma.
BJU Int. 2014 Feb;113(2):209-17.
Schröck A, Göke F, Wagner P, Bode M, Franzen A, Huss S, Agaimy A,
Ihrler S, Kirsten R, Kristiansen G, Bootz F, Lengerke C, Perner S.
Fibroblast-growth-factor-receptor-1 as a potential therapeutic target in
sinonasal cancer?
Head Neck. 2014 Sep;36(9):1253-7.
Nowak M, Svensson MA, Carlsson J, Vogel W, Kebschull M, Wernert N,
Kristiansen G, Andrén O, Braun M, Perner S.
Prognostic significance of phospho-histone H3 in prostate carcinoma.
World J Urol. 2014 Jun;32(3):703-7.
Peng W, Maintz L, Allam JP, Raap U, Gütgemann I, Kirfel J, Wardelmann
E, Perner S, Zhao W, Fimmers R, Walgenbach K, Oldenburg J, Schwartz
LB, Novak N.
Increased circulating levels of neurotrophins and elevated expression of
their high-affinity receptors on skin and gut mast cells in mastocytosis.
Blood. 2013 Sep 5;122(10):1779-88.
Bareiss PM, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U,
Rothfuss OC, Fischer A, Perner S, Staebler A, Wallwiener D, Fend F,
Fehm T, Pichler B, Kanz L, Quintanilla-Martinez L, Schulze-Osthoff K,
Essmann F, Lengerke C.
SOX2 expression associates with stem cell state in human ovarian
carcinoma.
Cancer Res. 2013 Sep 1;73(17):5544-55.
Lehnen NC, von Mässenhausen A, Kalthoff H, Zhou H, Glowka T, Schütte
U, Höller T, Riesner K, Boehm D, Merkelbach-Bruse S, Kirfel J, Perner S,
Gütgemann I.
Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal
adenocarcinoma.
Histopathology. 2013 Aug;63(2):157-66.
Pham DL, Scheble V, Bareiss P, Fischer A, Beschorner C, Adam A,
Bachmann C, Neubauer H, Boesmueller H, Kanz L, Wallwiener D, Fend
F, Lengerke C, Perner S, Fehm T, Staebler A.
SOX2 Expression and Prognostic Significance in Ovarian Carcinoma.
Int J Gynecol Pathol. 2013 Jul;32(4):358-67.
Sailer V, Stephan C, Wernert N, Perner S, Jung K, Dietel M, Kristiansen
G.
Comparison of p40 (ΔNp63) and p63 expression in prostate tissues –
which one is the superior diagnostic marker for basal cells?
Histopathology. 2013 Jul;63(1):50-6.
Göke F, Bode M, Franzen A, Kirsten R, Goltz D, Göke A, Sharma R,
Boehm D, Vogel W, Wagner P, Lengerke C, Kristiansen G, Kirfel J, Van
Bremen T, Bootz F, Heasley LE, Schröck A, Perner S.
Fibroblast growth factor receptor 1 amplification is a common event in
squamous cell carcinoma of the head and neck.
Mod Pathol. 2013 Oct;26(10):1298-306.
Schröck A, Göke F, Wagner P, Bode M, Franzen A, Braun M, Huss S,
Agaimy A, Ihrler S, Menon R, Kirsten R, Kristiansen G, Bootz F, Lengerke
C, Perner S.
Sex Determining Region Y-Box 2 (SOX2) Amplification Is an Independent
Indicator of Disease Recurrence in Sinonasal Cancer.
PLoS One. 2013;8(3):e59201.
Braun M, Stomper J, Kirsten R, Shaikhibrahim Z, Vogel W, Böhm D,
Wernert N, Kristiansen G, Perner S.
Landscape of chromosome number changes in prostate cancer
progression.
World J Urol. 2013 Dec;31(6):1489-95.
Nowak M, Krämer B, Haupt M, Papapanou PN, Kebschull J, Hoffmann P,
Schmidt-Wolf IG, Jepsen S, Brossart P, Perner S, Kebschull M.
Activation of Invariant NK T Cells in Periodontitis Lesions.
J Immunol. 2013 Mar 1;190 (5):2282-91.
Braun M, Kirsten R, Rupp NJ, Moch H, Fend F, Wernert N, Kristiansen G,
Perner S.
Quantification of protein expression in cells and cellular subcompartments
on immunohistochemical sections using a computer supported image
analysis system.
Histol Histopathol. 2013 May;28(5):605-10.
Mosquera JM, Beltran H, Park K, Macdonald TY, Robinson BD, Tagawa
ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM,
Rubin MA.
Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of
Lethal Treatment-Related Neuroendocrine Prostate Cancer.
Neoplasia. 2013 Jan;15(1):1-10.
Dietrich D, Hasinger O, Bañez LL, Sun L, van Leenders GJ, Wheeler TM,
Bangma CH, Wernert N, Perner S, Freedland SJ, Corman JM, Ittmann
MM, Lark AL, Madden JF, Hartmann A, Schatz P, Kristiansen G.
Development and Clinical Validation of a Real-Time PCR Assay for PITX2
DNA Methylation to Predict Prostate-Specific Antigen Recurrence in
Prostate Cancer Patients Following Radical Prostatectomy.
J Mol Diagn. 2013 Mar;15(2):270-9.
Krämer B, Kebschull M, Nowak M, Demmer RT, Haupt M, Körner C,
Perner S, Jepsen S, Nattermann J, Papapanou PN.
Role of the NK cell-activating receptor CRACC in Periodontitis.
Infect Immun. 2013 Mar;81(3):690-6.
Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D,
Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S.
Differences in Frequency of ERG Oncoprotein Expression Between Index
Tumors of Caucasian and African American Patients With Prostate
Cancer.
Urology. 2012 Oct;80(4):749-53.
Menon R, Deng M, Boehm D, Braun M, Fend F, Boehm D, Biskup S,
Perner S.
Exome Enrichment and SOLiD Sequencing of Formalin Fixed Paraffin
Embedded (FFPE) Prostate Cancer Tissue.
Int J Mol Sci. 2012;13(7):8933-42.
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH,
Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I,
Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker
C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening
I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S,
Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G,
Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel
P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA,
Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E,
Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J,
Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH,
Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P,
Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider
PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R,
Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas
S, Thomas RK.
Integrative genome analyses identify key somatic driver mutations of
small-cell lung cancer.
Nat Genet. 2012 Oct;44(10):1104-10.
Shaikhibrahim Z, Ochsenfahrt J, Fuchs K, Kristiansen G, Perner S,
Wernert N.
ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1,
in prostate cancer.
Int J Mol Med. 2012 Nov;30(5):1029-33.
Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N,
Jung K, Stephan C, Kristiansen G.
Loss of SLC45A3 protein (prostein) expression in prostate cancer is
associated with SLC45A3-ERG gene rearrangement and an unfavorable
clinical course.
Int J Cancer. 2013 Feb 15;132(4):807-12.
Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K,
Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G,
Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.
ERG rearrangement in local recurrences compared to distant metastases
of castration-resistant prostate cancer.
Virchows Arch. 2012 Aug;461(2):157-62.
Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz
K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén
S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F,
Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C,
Sos M, Stoelben E, Wolf J, Zander T, Buettner R.
Definition of a fluorescence in-situ hybridization score identifies high- and
low-level FGFR1 amplification types in squamous cell lung cancer.
Mod Pathol. 2012 Nov;25(11):1473-80.
Braun M, Stomper J, Boehm D, Vogel W, Scheble VJ, Wernert N,
Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.
Improved Method of Detecting the ERG Gene Rearrangement in Prostate
Cancer Using Combined Dual-Color Chromogenic and Silver in Situ
Hybridization.
J Mol Diagn. 2012 Jul;14(4):322-7.
Shaikhibrahim Z, Braun M, Nikolov P, Boehm D, Scheble V, Menon R,
Fend F, Kristiansen G, Perner S, Wernert N.
Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a
clonal event during prostate cancer progression.
Hum Pathol. 2012 Nov;43(11):1910-6.
Goeke F, Franzen A, Menon R, Goltz D, Kirsten R, Boehm D, Vogel W,
Goeke A, Scheble V, Ellinger J, Gerigk U, Fend F, Wagner P, Schroeck
A, Perner S.
Rationale for treatment of metastatic squamous cell carcinoma of the lung
using FGFR Inhibitors.
Chest. 2012 Oct;142(4):1020-6.
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, Macdonald TY,
Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille
A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y,
Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA.
Molecular Characterization of Neuroendocrine Prostate Cancer and
Identification of New Drug Targets.
Cancer Discov. 2011 Nov;1(6):487-495.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Böhm D, Scheble V, Sotlar
K, Fend F, Tan SH, Dobi A, Kristiansen G, Wernert N, Perner S.
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer-a comparative study of two monoclonal
antibodies.
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9.
Braun M, Menon R, Nikolov P, Kirsten R, Petersen K, Schilling D, Schott
C, Gundisch S, Fend F, Becker KF, Perner S.
The HOPE fixation technique – a promising alternative to common
prostate cancer biobanking approaches.
BMC Cancer. 2011 Dec 7;11:511.
Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R,
Perner S, Wernert N.
The peripheral zone of the prostate is more prone to tumor development
than the transitional zone: Is the ETS family the key?
Mol Med Report. 2012 Feb;5(2):313-6.
Mosquera JM, Cin PD, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin
MA, Hirsch MS.
Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation
Renal Cell Carcinomas.
Diagn Mol Pathol. 2011 Sep;20(3):129-37.
Barry M, Dhillon PK, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth
T, Mucci LA, Rubin MA.
α-Methylacyl-CoA racemase expression and lethal prostate cancer in the
Physicians‘ Health Study and Health Professionals Follow-up Study.
Prostate. 2012 Feb;72(3):301-6.
Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K,
Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G,
Rubin MA, Fend F, Perner S.
Relevance of cohort design for studying the frequency of the ERG
rearrangement in prostate cancer.
Histopathology. 2011 Jun;58(7):1028-1036.
Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F,
Schneider F, Petersen K, Wallwiener D, Kanz L, Fend F, Perner S,
Bareiss PM, Staebler A.
Expression of the embryonic stem cell marker SOX2 in early-stage breast
carcinoma.
BMC Cancer. 2011 Jan 28;11:42.
Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR,
Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur
S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE,
Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci
LA.
mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate
Cancer.
J Clin Oncol. 2011 Jun 10;29(17):2391-6.
Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R,
Reischl M, Mikut R, Rubin MA, Fend F, Moch H, Soltermann A, Weder W,
Altorki NK, Perner S.
Frequency and clinicopathologic correlates of KRAS amplification in nonsmall
cell lung carcinoma.
Lung Cancer. 2011 Oct;74(1):118-23.
Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S,
Reischl M, Mikut R, Altorki NK, Moch H, Fend F, Staebler A, Bass AJ,
Meyerson M, Rubin MA, Soltermann A, Lengerke C, Perner S.
SOX2 gene amplification and protein overexpression are associated with
better outcome in squamous cell lung cancer.
Mod Pathol. 2011 Jul;24(7):944-53.
Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, Menon R,
Nikolov P, Petersen K, Beschorner C, Moch H, Kakies C, Protzel C,
Bauer J, Soltermann A, Fend F, Staebler A, Lengerke C, Perner S.
SOX2 amplification is a common event in squamous cell carcinomas of
different organ sites.
Hum Pathol. 2011 Aug;42(8):1078-88.
Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S,
Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA,
Rubin MA, Demichelis F.
ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3
in Prostate Cancer Disease Progression.
Neoplasia. 2010 Dec;12(12):1031-40.
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich
RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F,
Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings
S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I,
Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B,
Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, EngelRiedel
W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens
W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio
C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M,
Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S,
Thomas RK.
Frequent and Focal FGFR1 Amplification Associates with Therapeutically
Tractable FGFR1 Dependency in Squamous Cell Lung Cancer.
Science Transl Med. 2010 Dec 15;2(62):62ra93.
Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D,
Reischl M, Seitz G, Fend F, Kristiansen G, Perner S.
ERG rearrangement in small cell prostatic and lung cancer.
Histopathology. 2010 Jun;56(7):937-43.
Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T,
Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F,
Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S.
ERG rearrangement is specific to prostate cancer and does not occur in
any other common tumor.
Mod Pathol. 2010 Aug;23(8):1061-7.
Gakis G, Schilling D, Perner S, Schwentner C, Sievert KD, Stenzl A.
Sequential resection of malignant ureteral margins at radical cystectomy:
a critical assessment of the value of frozen section analysis.
World J Urol. 2011 Aug;29(4):451-6.
Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y,
Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M,
Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR,
Rubin MA, Andren O.
Molecular sampling of prostate cancer: a dilemma for predicting disease
progression.
BMC Med Genomics. 2010 Mar 16;3:8.
Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin
WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC,
Duncan LM, Rubin MA, Fisher DE, Garraway LA.
An oncogenic role for ETV1 in melanoma.
Cancer Res. 2010 Mar 1;70(5):2075-84.
Esgueva R*, Perner S*, J Lafargue C, Scheble V, Stephan C, Lein M,
Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a
large prostatectomy cohort.
Mod Pathol. 2010 Apr;23(4):539-46.
*equally contributed
Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC,
Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin
MA.
ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate
Cancer.
Urology. 2010 Apr;75(4):762-7.
Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm
SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON.
Human prostate sphere-forming cells represent a subset of basal
epithelial cells capable of glandular regeneration in vivo.
Prostate. 2010 Apr 1;70(5):491-501.
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim
SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA,
Getz G, Beroukhim R, O’Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz
P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C,
Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD,
Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O,
Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC,
Beer DG, Rustgi AK, Meyerson M.
SOX2 is an amplified lineage-survival oncogene in lung and esophageal
squamous cell carcinomas.
Nat Genet. 2009 Nov;41(11):1238-42.
Wagner PL*, Perner S*, Rickman DS, LaFargue CJ, Kitabayashi N,
Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA.
In situ evidence of KRAS amplification and association with increased p21
levels in non-small cell lung carcinoma.
Am J Clin Pathol. 2009 Oct;132(4):500-5.
*equally contributed
Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson
LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R,
Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG,
Wagner P, Wistuba II, Rubin MA, Meyerson M.
Amplification of chromosomal segment 4q12 in non-small cell lung
cancer.
Cancer Biol Ther. 2009 Nov;8(21):2042-50.
Gust KM, Hofer MD, Perner S, Kim R, Chinnaiyan AM, Varambally S,
Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer
M.
RHAMM (CD168) is overexpressed at the protein level and may
constitute an immunogenic antigen in advanced prostate cancer disease.
Neoplasia. 2009 Sep;11(9):956-63.
Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson
MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK,
Demichelis F, Chee MS, Gerstein MB, Rubin MA.
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in
prostate cancer.
Neoplasia. 2009 Aug;11(8):804-11.
Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ,
Balk SP, Rubin M, Sanda MG.
Detection of TMPRSS2-ERG fusion gene expression in prostate cancer
cpecimens by a novel assay using branched DNA.
Urology. 2009 Nov;74(5):1156-61.
Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G,
Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA,
Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.
Prevalence of TMPRSS2-ERG fusion prostate cancer among men
undergoing prostate biopsy in the United States. Clin Cancer Res. 2009
Jul 15;15(14):4706-11.
Touma SE, Perner S, Rubin MA, Nanus DM, Gudas LJ.
Retinoid metabolism and aldh1a2 (raldh2) expression are altered in the
transgenic adenocarcinoma mouse prostate model.
Biochem Pharmacol. 2009 1;78(9):1127-38.
Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma
J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA.
Gleason score and lethal prostate cancer: Does 3 + 4 = 4 + 3?
J Clin Oncol. 2009 Jul 20;27(21):3459-64.
Mukherjee S, Wysock JS, Ng CK, Akhtar M, Perner S, Lee MM, Rubin
MA, Maxfield FR, Webb WW, Scherr DS.
Human bladder cancer diagnosis using multiphoton microscopy.
Proc Soc Photo Opt Instrum Eng. 2009;7161:nihpa96839.
Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ,
Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS,
Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin
MA.
Distinct genomic aberrations associated with ERG rearranged prostate
cancer.
Genes Chromosomes Cancer. 2009 Jan 20;48(4):366-380.
Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, Ma
J, Fleet J, Kurth T, Rubin MA, Mucci LA.
Aberrant cytoplasmic expression of p63 and prostate cancer mortality.
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):595-600.
Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F,
Paiss T, Vogel W, Rubin MA, Hoegel J.
Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial
prostate cancer.
Cancer Res. 2009 Jan 15;69(2):640-6.
Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA,
Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR.
Clinical significance of TTF-1 protein expression and TTF-1 gene
amplification in lung adenocarcinoma.
J Cell Mol Med. 2009 Aug;13(8B):1977-86.
Perner S, Wagner P, Soltermann A, Lafargue C, Tischler V, Weir B,
Weder W, Meyerson M, Giordano T, Moch H, Rubin M.
TTF1 expression in non-small cell lung carcinoma: association with TTF1
gene amplification and improved survival.
J Pathol. 2009 Jan;217(1):65-72.
Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G,
Simko J, Carroll P, Rubin MA, Collins C.
An oncogenic role for the multiple endocrine neoplasia type 1 gene in
prostate cancer
Prostate Cancer Prostatic Dis. 2009;12(2):184-91.
Lenkinski RE, Bloch BN, Liu F, Frangioni JV, Perner S, Rubin MA,
Genega EM, Rofsky NM, Gaston SM. An illustration of the potential for
mapping MRI/MRS parameters with genetic over-expression profiles in
human prostate cancer.
MAGMA. 2008 Nov;21(6):411-21.
Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO,
Andersson SO, Andrén O, Eisenstein A, Holmberg L, Huang W, Kantoff
PW, Kim R, Perner S, Stampfer MJ, Johansson JE, Rubin MA.
Testing a Multigene Signature of Prostate Cancer Death in the Swedish
Watchful Waiting Cohort.
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1682-8.
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S,
Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X,
Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham
JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A,
Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA,
Bjartell AS, Chinnaiyan AM.
The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Cancer Cell. 2008 Jun;13(6):519-28.
Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD,
Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA.
Characterization of TMPRSS2-ERG fusion high-grade prostatic
intraepithelial neoplasia and potential clinical implications.
Clin Cancer Res. 2008 Jun 1;14(11):3380-5.
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S,
Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza
S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW,
Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M,
Golub TR, Rubin MA.
Estrogen-dependent signaling in a molecularly distinct subclass of
aggressive prostate cancer.
J Natl Cancer Inst. 2008 Jun 4;100(11):815-25.
Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assum G,
Paiss T, Hoegel J, Vogel W, Maier C.
Expression changes of CAV1 and EZH2, located on 7q31 approximately
q36, are rarely related to genomic alterations in primary prostate
carcinoma.
Cancer Genet Cytogenet. 2008 Apr 15;182(2):103-10.
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ,
Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman
DS, Chinnaiyan AM, Moch H, Rubin MA. EML4-ALK fusion lung cancer: a
rare acquired event.
Neoplasia. 2008 Mar;10(3):298-302.
Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO,
Andersson SO, Andrén O, Eisenstein AS, Holmberg L, Huang W,
Kantoff PW, Perner S, Stampfer MJ, Johansson JE, Rubin MA.
Nine-gene molecular signature is not associated with prostate cancer
death in a watchful waiting cohort.
Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):249-51.
Sträter J, Wiesmüller C, Perner S, Kuefer R, Möller P.
alpha-Methylacyl-CoA racemase (AMACR) immunohistochemistry in
Barrett’s and colorectal mucosa: only significant overexpression favours
a diagnosis of intraepithelial neoplasia.
Histopathology. 2008 Feb;52(3):399-402.
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D,
Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK,
Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F,
Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS,
Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK,
Sellers WR.
Assessing the significance of chromosomal aberrations in cancer:
Methodology and application to glioma.
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12.
Barry M, Perner S, Demichelis F, Rubin MA.
TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer:
Clinical and Biologic Implications.
Urology. 2007 Oct;70(4):630-633.
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM,
Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK,
Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac
LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M,
Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER,
McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne
JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki
H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak
RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S,
Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway
LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA,
Varmus HE, Wilson RK, Lander ES, Meyerson M.
Characterizing the cancer genome in lung adenocarcinoma.
Nature. 2007 Dec 6;450(7171):893-8.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J,
Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
TMPRSS2-ERG fusion prostate cancer: an early molecular event
associated with invasion.
Am J Surg Pathol. 2007 Jun;31(6):882-8.
Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S,
Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C,
Chinnaiyan AM, Rubin MA.
Molecular characterization of TMPRSS2-ERG gene fusion in the NCIH660
prostate cancer cell line: a new perspective for an old model.
Neoplasia. 2007 Mar;9(3):200-6.
Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD,
Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
J Pathol. 2007 May;212(1):91-101.
Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE,
Gschwend JE, Kuefer R, Rubin MA.
Prostate-specific membrane antigen expression as a predictor of
prostate cancer progression.
Hum Pathol. 2007 May;38(5):696-701.
Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida
Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW,
Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA.
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a
watchful waiting cohort.
Oncogene. 2007 Jul 5;26(31):4596-9.
Polzehl D, Moeller P, Riechelmann H, Perner S.
Distinct features of chronic rhinosinusitis with and without nasal polyps.
Allergy. 2006 Nov;61(11):1275-9.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur
S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R,
Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.
TMPRSS2:ERG fusion-associated deletions provide insight into the
heterogeneity of prostate cancer.
Cancer Res. 2006 Sep 1;66(17):8337-41.
Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F,
Kocot D, Moller P, Glatting G, Perner S.
Imaging prostate cancer with 11C-choline PET/CT.
J Nucl Med. 2006 Aug;47(8):1249-54.
Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE,
Sanda MG, Gschwend JE, Rubin MA.
Prognostic factors in lymph node-positive prostate cancer.
Urology. 2006 May;67(5):1016-21.
Mayer S, Bruderlein S, Perner S, Waibel I, Holdenried A, Ciloglu N, Hasel
C, Mattfeldt T, Nielsen KV, Moller P.
Sex-specific telomere length profiles and age-dependent erosion
dynamics of individual chromosome arms in humans.
Cytogenet Genome Res. 2006;112(3-4):194-201.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun
XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah
RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in
prostate cancer.
Science. 2005 Oct 28;310(5748):644-8.
Perner S, Bruderlein S, Hasel C, Waibel I, Holdenried A, Ciloglu N,
Chopurian H, Nielsen KV, Plesch A, Hogel J, Moller P.
Quantifying telomere lengths of human individual chromosome arms by
centromere-calibrated fluorescence in situ hybridization and digital
imaging.
Am J Pathol. 2003 Nov;163(5):1751-6.
Hasel C, Rau B, Perner S, Strater J, Moller P.
Differential and mutually exclusive expression of CD95 and CD95 ligand
in epithelia of normal pancreas and chronic pancreatitis.
Lab Invest. 2001 Mar;81(3):317-26.
Buchkapitel und Reviews:
Boehm D, von Mässenhausen A, Perner S.
Analysis of Receptor Tyrosine Kinase Gene Amplification on the Example
of FGFR1.
Methods Mol Biol. 2015;1233:67-79. Book chapter in: Receptor Tyrosine
Kinases – Methods and Protocols, Springer Protocols, Humana Press;
Editor: Serena Germano
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles
RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, Vecchia CL, Lilja H,
Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner
S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder
FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.
Prevention and early detection of prostate cancer.
Lancet Oncol. 2014 Oct;15(11):e484-92. Review.
Braun M, Perner S.
Epidemiology and etiology of prostate cancer.
Tumor Diagnostik und Therapie. 2012 Oct 33:394-398. Review. German
Göke F, Perner S.
Translational research and diagnostics in lung cancer.
Pathologe. 2012 Nov;33 Suppl 2:269-72. Review. German.
Braun M, Perner S.
High-grade prostatic intraepithelial neoplasia: The only accepted prostate
cancer precursor lesion.
Pathologe. 2011 Nov;32 Suppl 2:237-41. Review. German.
Menon R, Braun M, Perner S.
ERG (v-ets erythroblastosis virus E26 oncogene like (avian))
Atlas Genet Cytogenet Oncol Haematol. Nov. 2010. Review.
Perner S. Dangerous liaisons in prostate cancer. Clinical and biological
implications of recurrent gene fusions.
Pathologe. 2010 Oct;31 Suppl 2:121-5. Review. German
Wilbertz T, Maier S, Perner S.
NKX2-1 (NK2 homeobox 1) (aka TTF1 oder TITF1)
Atlas Genet Cytogenet Oncol Haematol. April 2010. Review.
Perner S, Wilbertz T, Stiedl AC, Rubin MA.
EML4 (echinoderm microtubule associated protein like 4).
Atlas Genet Cytogenet Oncol Haematol. July 2009. Review.
Schmidt F, Scheble V, Mertz K, Perner S, Rubin MA.
Gene fusion in prostate cancer: clinical applications in diagnosis,
prognosis and therapy.
Dtsch Med Wochenschr. 2009 Jul;134(28-29):1483-6. Review. German.
Perner S, Mertz KD, Kuefer R, Rubin MA
Biomarkers for Prostate Cancer – Molecular Approaches to asses
Prognosis
Onkologe. 2007 Aug;(13(8):669-676. Review. German.
Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M.
TMPRSS2-ETS gene fusion in prostate cancer
Urologe A. 2007 Jul;46(7):754-60. Review. German.
Mertz KD, Tchinda J, Kufer R, Moller P, Rubin MA, Moch H, Perner S.
Cytogenetic alterations in renal tumors. Applications for comparative
genomic hybridization and fluorescence in situ hybridization
Urologe A. 2006 Mar;45(3):316-8, 320-2. Review. German.
Case Reports:
Stahl S, Stahl AS, Lotter O, Pfau M, Perner S, Schaller HE.
Palliative surgery for skeletal metastases from melanoma in the scaphoid
– A critical case report appraisal.
J Plast Reconstr Aesthet Surg. 2012 Aug;65(8):1111-5.
Lepper PM, Koenig W, Moller P, Perner S.
A case of sudden cardiac death due to isolated eosinophilic coronary
arteritis.
Chest. 2005 Aug;128(2):1047-50.
Einsiedel T, Liener U, Brinkmann A, Trager K, Liewald F, Perner S, Kinzl
L, Gebhard F.
Fatal outcome after multiple trauma. The thoracic injury as the decisive
factor
Unfallchirurg. 2003 Sep;106(9):771-6. German.
Wellinghausen N, Sing A, Kern WV, Perner S, Marre R, Rentschler J.
A fatal case of necrotizing sinusitis due to toxigenic Corynebacterium
ulcerans.
Int J Med Microbiol. 2002 Jun;292(1):59-63.
Editorials, Letters and Author Replies:
von Mässenhausen A, Franzen A, Heasley L, Perner S.
FGFR1 as a novel prognostic and predictive biomarker in squamous cell
cancers of the lung and the head and neck area.
Ann Transl Med. 2013 Oct;1(3):23.
Shaikhibrahim Z, Offermann A, Perner S.
Re: punctuated evolution of prostate cancer genomes.
Eur Urol. 2014 Mar;65(3):666-7.
Perner S, Rubin MA.
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer
with implications for molecular diagnosis.
Letter to the Editor regarding Lapointe et al.
Mod Pathol. 2008 21:1056-1057; author reply 1056-7.
Perner S, Rubin MA.
In Response to: Teixeira MR. Chromosome mechanisms giving rise to the
TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions.
Am J Surg Pathol. 2008 Apr;32(4):642-4; author reply 644.
Kongressbeiträge als präsentierender Autor oder Seniorautor
Boehm D, Shaikhibrahim Z, Offermann A, Deng M, Queisser A, Perner S.
Genomic analysis of the Mediator complex identifies a frequent
concomitant copy number gain of MED12L and SOX2 in head and neck
squamous cell cancer
7th Mildred Scheel Cancer Conference, Königswinter near Bonn, 2015,
Poster presentation
Offermann A, Shaikhibrahim Z, Braun M, Syring I, Vogel W, Ruiz C, Zellweger T,
Rentsch CA, Bubendorf L, Perner S.
The role of the Mediator complex subunit MED15 in castration-resistant prostate
cancer
7th Mildred Scheel Cancer Conference, Königswinter near Bonn, 2015,
Poster presentation
Nowak M, Merz C, von Maessenhausen A, Vogel W, Perner S.
Role of trefoil factor-3 peptide (TFF3) in prostate cancer progression
7th Mildred Scheel Cancer Conference, Königswinter near Bonn, 2015,
Poster presentation
von Mässenhausen A, Deng M, Vogel W, Kristiansen G, Schröck A,
Bootz F, Queisser A, Perner S.
Rezeptor Tyrosin Kinasen als neue therapeutische Ziele in
Plattenepithelkarzinomen des Kopf-Hals Bereichs
7th Mildred Scheel Cancer Conference, Königswinter near Bonn, 2015,
Poster presentation
Klümper N, Syring I, Offermann A, Braun M, Deng M, Böhm D, Queisser
A, von Mäßenhausen A, Nowak M, Vogel W, Ellinger J, Müller SC,
Shaikhibrahim Z, Perner S.
The downregulation of MED12 is implicated in the progression and
metastasis of urinary bladder cancer.
7th Mildred Scheel Cancer Conference, Königswinter near Bonn, 2015,
Poster presentation
Hagedorn S, Queisser A, Wang H, Vogel W, von Mässenhausen A,
Lengerke C, Perner S.
Ecotropic Viral Integration Site 1 as a New Tumor Stem Cell Like
Oncogene in Prostate Cancer
7th Mildred Scheel Cancer Conference, Königswinter near Bonn, 2015,
Poster presentation
Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M,
Böhm D, Queisser A, von Mäßenhausen A, Ellinger J, Müller SC, Perner
S.
Die Bedeutung der Mediator-Komplex Untereinheit MED12 während der
Progression des muskelinvasiven Blasenkarzinoms
Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie, Köln,
2015. Platform presentation
Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M,
Böhm D, Queisser A, von Mäßenhausen A, Ellinger J, Müller SC, Perner
S.
The Mediator complex subunit MED12 is implicated in the progression of
urothelial cell carcinoma of the bladder
American Urological Association (AUA) Annual Meeting, New Orleans,
2015. Poster presentation
Böhm D, Shaikhibrahim Z, Offermann A, Deng M, Queisser A, Perner S.
Eine genomische Analyse des Mediator Komplexes zeigt eine häufige
Amplifikation von MED12L und SOX2 im Kopf Hals
Plattenepithelkarzinom
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Frankfurt, 2015. Platform presentation
Braun M, Deng M, Menon R, Vogel W, Boehm D, Perner S.
Whole Exome Sequencing of Matched Primary Prostate Cancer and
Lymph Node Metastases.
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Frankfurt, 2015. Poster presentation
Braun M, Deng M, Offermann A, Syring I, Shaikhibrahim Z, Perner S.
The Methylational Landscape of the Mediator Complex in Prostate
Cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Frankfurt, 2015. Platform presentation
Offermann A, Shaikhibrahim Z, Braun M, Syring I, Vogel W, Ruiz C,
Zellweger T, Rentsch C, Bubendorf L, Perner S.
MED15 overexpression in CRPC arises via activation of the
PI3K/AKT/mTOR pathway
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Frankfurt,
2015. Platform presentation
Klümper N, Syring I, Offermann A, Braun M, Deng M, Böhm D, Queisser
A, von Mäßenhausen A, Nowak M, Vogel W, Ellinger J, Müller SC,
Shaikhibrahim Z, Perner S.
The downregulation of MED12 is implicated in the progression and
metastasis of urinary bladder cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Frankfurt, 2015. Platform presentation
von Mässenhausen A, Deng M, Vogel W, Kristiansen B, Schröck A, Bootz
F, Queisser A, Perner S.
Receptor tyrosine kinases as novel therapeutic targets in head and neck
squamous cell carcinoma
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Frankfurt, 2015. Platform presentation
Syring I, Klümper N, Shaikhibrahim Z, Offermann A, Braun M, Deng M,
Böhm D, Queisser A, von Mäßenhausen A, Nowak M, Ellinger J, Müller
S, Perner S.
The Mediator complex subunit MED12 is implicated in the progression of
urothelial cell carcinoma of the urinary bladder
Kongress der European Association of Urology (EAU), Madrid, 2015.
Poster presentation.
Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Nowak M,
Halback, R, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O,
Bubendorf L, Biskup S, Kirfel J, Perner S. MED12 overexpression is a
frequent event in castration-resistant prostate cancer.
Kongress der European Association of Urology (EAU), Madrid, 2015.
Poster presentation.
Queisser A, Hagedorn S, Wang H, Vogel W, von Mäßenhausen A,
Lengerke C, Perner S.
Ecotropic Viral Integration Site 1 as a New Tumor Stem Cell Like
Oncogene in Prostate Cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2015. Poster presentation.
Braun M, Deng M, Menon R, Vogel W, Böhm D, Perner S.
Whole Exome Sequencing of Matched Primary Prostate Cancer and
Lymph Node Metastases.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2015. Poster presentation.
Offermann A, Shaikhibrahim Z, Braun M, Syring I, Vogel W, Ruiz C,
Zellweger T, Rentsch CA, Bubendorf L, Perner S.
MED15 overexpression arisis during androgen deprivation therapy via
PI3K/mTOR signaling.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2015. Poster presentation.
Braun M, Deng M, Offermann O, Syring I, Shaikhibrahim Z, Perner S.
The Methylational Landscape of the Mediator Complex in Prostate
Cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2015. Poster presentation.
Böhm D, Shaikhibrahim Z, Offermann A, Deng M, Perner S.
Mutational landscape of the Mediator complex across human cancers.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2015. Platform presentation.
von Mäßenhausen A, Deng M, Vogel W, Schröck A, Queisser A, Perner
S.
Receptor Tyrosine Kinases as Novel Therapeutic Targets in Head and
Neck Squamous Cell Carcinoma.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2015. Poster presentation.
Nowak M, Merz C, Svensson MA, Wernert N, Kristiansen G, Andrén O,
Perner S.
Role of trefoil factor-3 peptide (TFF3) in prostate cancer progression
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
Schröck A, Bode M, Franzen A, Heasley L, Lengerke C, Perner S.
Expression and role of the embryonic protein SOX2 in head and neck
squamous cell carcinoma
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
von Mässenhausen A, Deng M, Vogel W, Queisser A, Perner S.
Receptor tyrosine kinases as novel therapeutic targets in head and neck
squamous cell carcinoma
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
Shaikhibrahim Z, Boehm D, Offermann A, Deng M, Perner S.
Mutational landscape of the Mediator complex across human cancers
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
Offermann A, Shaikhibraim Z, Braun M, Menon R, Syring I, Vogel W,
Ruiz C, Zellweger T, Rentsch C, Svensson M, Andren O, Bubendorf L,
Biskup S, Duensing S, Kirfel J, Perner, S.
MED12 overexpression is a frequent event in castration-resistant prostate
cancer
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
Nowak M, Menon R, von Mässenhausen A, Merz C, Svensson MA,
Wernert N, Kristiansen G, Andren O, Perner S.
FoxF1 is a potential oncogene in prostate cancer
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
Queisser A, Hagedorn S, Vogel W, Böhm D, von Mässenhaussen A,
Lengerke C, Perner S.
The role of the transcription factor ecotropic viral integration site 1 in
prostate cancer
Kongress der European Association for Cancer Research (EACR),
München, 2014. Poster presentation.
Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Vogel W,
Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Kristiansen G,
Wernert N, Bubendorf L, Biskup S, Kirfel J, Perner S.
MED12 overexpression is a frequent event in castration-resitant prostate
cancer.
66. Kongress der Deutschen Gesellschaft für Urologie,
Düsseldorf, 2014. Platform presentation.
Hagedorn S, Queisser A, Vogel W, Böhm D, Lengerke C, Wernert N,
Kristiansen G, Perner S.
Expression of the Stem Cell Marker Ecotropic Viral Integration Site-1 in
Prostate Cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Poster presentation.
Nowak M, Merz C, Svensson MA, Wernert N, Kristiansen G, Andrén O,
Perner S.
Role of trefoil factor- 3 peptide (TFF3) in prostate cancer progression
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Plattform presentation.
Nowak M, Menon R, von Maessenhausen A, Merz C, Svensson MA,
Wernert N, Kristiansen G, Andrén O, Perner S.
FoxF1 is a potential oncogene in prostate cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Plattform presentation.
Braun M, Böhm D, Vogel W, Franzen A, Schröck A, Bootz F, Heaseley L,
Perner S.
FGFR1 dual-color chromogenic and silver in-situ Hybridization a new tool
for the detection of the FGFR1 copy number status
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Poster presentation.
Merz C, Nowak M, Vogel W, Svensson MA, Carlsson J, Andrén O,
Wernert N, Kristiansen G, Perner S.
The stimulating effect of Interleukin-6 in TMPRSS2-ERG positive prostate
cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Poster presentation.
Offermann A, Shaikhibraim Z, Braun M, Böhm D, Vogel W, Kristiansen G,
Schröck A, Perner, S.
MED15 Is Overexpressed at High Frequency in Head and Neck
Squamous Cell Carcinoma and Is Implicated in TGFß Signaling
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Plattform presentation.
Offermann A, Shaikhibraim Z, Braun M, Menon R, Syring I, Vogel W,
Ruiz C, Zellweger T, Rentsch C, Svensson M, Andren O, Bubendorf L,
Biskup S, Duensing S, Kirfel J, Perner, S.
MED12 overexpression is a frequent event in castration-resistant prostate
cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Plattform presentation.
Queisser A, Hagedorn S, Vogel W, Wernert N, Kristiansen G, Perner S.
The Use of Different Prostate-Specific Markers in the Diagnosis of
Metastatic Prostate Cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Berlin, 2014. Poster presentation.
Syring I, Shaikhibrahim Z, Offermann A, Braun M, Menon R, Vogel W,
Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L,
Biskup S, Kirfel J, Perner S.
MED12 Überexpression im kastrationsresistenten Prostatakarzinom
Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie,
Düsseldorf, 2014. Plattform presentation.
Braun M, Shaikhibrahim Z, Menon R, Offermann A, Queisser A, Böhm D,
Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson MA, Andren O,
Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.
MED15, encoding a subunit of the Mediator complex, is overexpressed at
high frequency in castration-resistant prostate cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2014. Poster presentation.
Svensson MA, Nowak M, Vogel W, Carlsson J, Andrén O, Perner S.
Combination of multiple markers predicts prostate cancer outcome.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2014. Poster presentation.
Braun M, Böhm D, Vogel W, Franzen A, Schröck, Bootz F, Heaseley LE,
Perner S.
FGFR1 dual-color chromogenic and silver in-situ hybridization – a new
tool for the detection of the FGFR1 copy number status.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2014. Poster presentation.
Merz C, Nowak M, Vogel W, Wernert N, Kristiansen G, Svensson MA,
Carlsson J, Andrén O, Perner S.
The stimulating effect of Interleukin-6 in TMPRSS2-ERG positive prostate
cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2014. Poster presentation.
Offermann A, Shaikhibrahim Z, Braun M, Schröck A, Böhm D, Vogel W,
Wernert N, Kristiansen G, Perner S.
MED15 is overexpressed at high frequency in head and neck squamous
cell carcinoma and is implicated in TGFß signaling.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2014. Poster presentation.
Offermann A, Shaikhibrahim Z, Braun M, Menon R, Böhm D, Vogel W,
Ruiz C, Zellweger T, Svensson M, Andren O, Kristiansen G, Wernert N,
Bubendorf L, Kirfel J, Biskup S, Perner S.
MED12 is a Potential Target for Therapeutic Intervention in Castration
Resistant Prostate Cancer
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2014. Plattform presentation.
Braun M, Shaikhibrahim Z, Menon R, Offermann A, Queisser A, Boehm
D, Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O,
Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.
MED15, encoding a subunit of the Mediator complex, is overexpressed at
high frequency in castration-resistant prostate cancer.
Jahreskongress der Deutschen Gesellschaft für Urologie (DGU),
Dresden, 2013. Poster presentation.
Göke A, Göke F, von Mässenhausen A, Franzen A, Böhm D, Weichert W,
Buettner R, Perner S.
FGFR1 amplification in primary and lymph node metastatic colorectal
cancer.
6th Mildred Scheel Cancer Conference, Königswinter, 2013. Poster
presentation.
Nowak M, Menon R, Kunze F, Perner S.
Analysis of the potential tumor suppressor FoxF1 in prostate cancer. 6th
Mildred Scheel Cancer Conference, Königswinter, 2013. Poster
presentation.
Rüenauver K, Menon R, Deng M, Kunze F, Boehm D, Vogel W, Scheble
V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin
MA, Shaikhibrahim Z, Perner S.
YWHAZ and PTK2 as Potential Therapeutic Targets in Castration
Resistant Prostate Cancer.
6th Mildred Scheel Cancer Conference, Königswinter, 2013. Poster
presentation.
Braun M, Shaikhibrahim Z, Menon R, Queisser A, Offermann A, Boehm D,
Vogel W, Rüenauver K, Ruiz C, Zellweger T, Svensson M, Andren O,
Kristiansen G, Wernert N, Bubendorf L, Kirfel J, Biskup S, Perner S.
MED15, encoding a subunit of the Mediator complex, is overexpressed at
high frequency in castration-resistant prostate cancer.
6th Mildred Scheel Cancer Conference, Königswinter, 2013. Poster
presentation.
Bode M, Schröck A, Bareiss MP, Göke F, Franzen A, Kirsten R, von
Mäßenhausen A., von Bremen T., Bootz F, Kristiansen G, Lengerke C,
Perner S.
SOX2 as a potential therapeutic target in squamous cell carcinoma of the
head and neck.
6th Mildred Scheel Cancer Conference, Königswinter 2013. Poster
presentation.
Franzen A, Göke F, Bode M; von Mässenhausen A, Göke A, Sharma R,
Vogel W, Böhm D, Bootz F, Kristiansen G, Schröck A, Perner S.
FGFR1 expression rather than amplification is the crucial predictive
marker for in-vitro sensitivity of HNSCC cells to FGFR small molecule
inhibitor treatment.
Kongress der Deutschen Gesellschaft für Pathologie (DGP),
Heidelberg, 2013. Poster presentation.
Rüenauver K, Menon R, Deng M, Kunze F, Boehm D, Vogel W, Scheble
V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin
MA, Shaikhibrahim Z, Perner S.
Whole Exome Sequencing identifies YWHAZ and PTK2 as Potential
Therapeutic Targets in Castration Resistant Prostate Cancer
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Heidelberg,
2013. Plattform presentation.
Bode M, Schröck A, Bareiss MP, Göke F, Franzen A, Kirsten R, von
Mäßenhausen A, von Bremen T, Bootz F, Kristiansen G, Lengerke C,
Perner S.
SOX2 as a potential therapeutic target in squamous cell carcinoma of the
head and neck
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Heidelberg,
2013. Plattform presentation.
Nowak M, Braun M, Vogel W, Svensson M, Andren O, Wernert N,
Kristiansen G, Perner, S.
Phospho-Histone H3 Expression im Prostatakarzinom
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Heidelberg,
2013. Poster presentation.
Braun M, Weiss LV, Harz A, Vorreuther R, Kristiansen G, Müller CS,
Ellinger J, Perner S.
Prognostic significance of tumor thrombus consistency in patients with
renal cell carcinoma
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Heidelberg,
2013. Poster presentation.
Shaikhibrahim Z, Menon R, Braun M, Queisser A, Böhm D, Rüenauver
K, Kunze F, Vogel W, Wernert N, Kristiansen G, Perner S.
The Mediator complex subunit MED12 is a novel target for therapeutic
intervention in castration resistant prostate cancer Kongress der
Deutschen Gesellschaft für Pathologie (DGP), Heidelberg, 2013. Poster
presentation.
Rüenauver K, Menon, Deng M, Kunze F, Boehm D, Vogel W, Scheble V,
Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin
MA, Shaikhibrahim Z, Perner S.
Somatic Copy Number Alterations by Whole Exome Sequencing Reveals
YWHAZ and PTK2 as Potential Therapeutic Targets in Castration
Resistant Prostate Cancer
Kongress der United States and Canadian Academy of Pathology
(USCAP), Baltimore, 2013. Poster presentation.
Bode M, Schröck A, Bareiss PM, Göke F, Franzen A, Kirsten R, von
Mäßenhausen A, von Bremen T, Bootz F, Kristiansen G, Lengerke C,
Perner S.
SOX2 as a potential therapeutic target in squamous cell carcinoma of the
head and neck.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Baltimore, 2013. Poster presentation.
Menon R, Deng M, Ruenauver K, Kunze F, Boehm D, Vogel W, Scheble
V, Fend F, Kristiansen G, Wernert N, Boehm D, Biskup S, Rubin MA,
Shaikhibrahim Z, Perner S.
Somatic copy number alterations by whole exome sequencing reveals
YWHAZ and PTK2 as potential therapeutic targets in castration resistant
prostate cancer
American Association of Cancer Research (AACR) Special Conference
on Tumor Invasion and Metastasis, San Diego, USA 2013. Poster
presentation.
Kunze F, Rüenauver K, Menon R, Deng M, Boehm D, Vogel W, Scheble
V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin
MA, Shaikhibrahim Z, Perner S.
Somatic copy number alterations by whole exome sequencing reveals
YWHAZ and PTK2 as potential therapeutic targets in castration resistant
prostate cancer
Symposium der Arbeitsgruppe für urologische Forschung (AuF) der
Deutschen Gesellschaft für Urologie (DGU), Berlin, 2012, Plattform
presentation.
Goeke F, Franzen A, Menon R, Kirsten R, Scheble V, Goltz D, Kirsten R,
Boehm D, Vogel W, Schroeck A, Perner S.
Rational for treatment of metastatic squamous cell carcinoma of the
lung using FGFR Inhibitors.
24th European Congress of Pathology (ECP), Prague, 2012. Plattform
presentation.
Goeke F, Franzen A, Menon R, Kirsten R, Boehm D, Vogel W, Bootz F,
Schroeck A, Perner S.
FGFR1 amplification in metastatic squamous cell carcinoma of the head
and neck – a potential target for a rational therapy?
24th European Congress of Pathology (ECP), Prague, 2012. Plattform
presentation.
Menon R, Deng M, Ruenauver K, Kunze F, Boehm D, Vogel W, Schaeble
F, Fend F, Kristiansen G, Wernert N, Beohm D, Biskup S, Rubin M,
Shaikhibrahim Z, Perner S.
Somatic copy number alterations by whole exome sequencing reveals
YWHAZ and PTK2 as potential therapeutic targets in castration resistant
prostate cancer
European Congress for Pathology (ECP), Prague
2012. Plattform presentation.
M. Braun, Z. Shaikhibrahim, P. Nikolov, D. Boehm, V. Scheble, R. Menon,
F. Fend, G. Kristiansen, N. Wernert, S. Perner.
Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5 and ELK-1 is a
clonal event during prostate cancer progression.
24. Kongress der European Society of Pathology (ESP), Prague, 2012.
Plattform presentation.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Boehm D, Scheble V, Dobi
A, Fend F, Wernert N, Kristiansen G, Perner S.
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer a comparative study of two monoclonal
antibodies.
24. Kongress der European Society of Pathology (ESP), Prague, 2012.
Plattform presentation.
Braun M, Stomper J, Boehm D, Vogel W, Scheble V, Wernert N,
Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.
Improved method of detecting the ERG gene rearrangement in prostate
cancer using combined dual-color chromogenic and silver in-situ
hybridization.
24. Kongress der European Society of Pathology (ESP), Prague, 2012.
Plattform presentation.
Braun M, Kirsten R, Rupp N, Deng M, Moch H, Kristiansen G, Perner S.
Quantification of Protein Expression in Immunohistochemical Sections
using a newly launched Image Analysis Software. 24. K ongress der
European Society of Pathology (ESP), Prague, 2012. Plattform
presentation.
Braun M, Stomper J, Vogel W, Scheble V, Fend F, Perner S.
Landscape of Chromosome Number Changes during Prostate Cancer
Progression. European 24. K ongress der Society of Pathology (ESP),
Prague, 2012. Plattform presentation.
Stomper J, Braun M, Kirsten R, Vogel W, Boehm D, Wernert N,
Shaikhibrahim Z, Kristiansen G, Perner S.
Landscape of chromosome number changes and proliferative activity in
prostate cancer progression
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2012.
Plattform presentation.
Goeke F, Franzen A, Menon R, Kirsten R, Boehm D, Vogel W, Bootz F,
Schroeck A, Perner S.
FGFR1 amplification in metastatic squamous cell carcinoma of the head
and neck – a potential target for a rational therapy?
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Plattform presentation.
Goeke F, Franzen A, Menon R, Huss S, Boehm D, Vogel W, Bootz F,
Ihrler S, Schroeck A, Perner S.
SOX2 amplification is a common event in sinunasal squamous cell and
undifferentiated carcinomas.
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Plattform presentation.
Menon R , Deng M , Boehm D, Fend F, Boehm D , Biskup S , Perner S.
Whole exome sequencing identifies potential therapeutic targets for
castration resistant prostate cancer.
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Plattform presentation.
Goeke A , Goeke F, Von Messenhausen A, Menon R, Boehm D, Weichert
W, Buettner R, Perner S.
FGFR1 amplification in primary and lymph node metastatic colorectal
cancer.
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Poster presentation.
Franzen A, Goeke F, Goeke A, Menon R, Golletz C, Kirsten R, Boehm D,
Vogel W, Schroeck A, Perner S.
Rationale for Treatment of Metastatic Squamous Cell Lung Cancer with
FGFR Inhibitors
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Plattform presentation.
Braun M, Shaikhibrahim Z, Nikolov P, Boehm D, Scheble V, Menon R,
Fend F, Kristiansen G, Wernert N, Perner S.
Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5 and ELK-1 is a
clonal event during prostate cancer progression.
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Poster presentation.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Boehm D, Scheble V, Dobi
A, Fend F, Wernert N, Kristiansen G, Perner S.
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer a comparative study of two monoclonal
antibodies.
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Poster presentation.
Braun M, Stomper J, Boehm D, Vogel W, Scheble V, Wernert N,
Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.
Improved method of detecting the ERG gene rearrangement in prostate
cancer using combined dual-color chromogenic and silver in-situ
hybridization.
Kongress der Deutschen Gesellschaft für Pathologie (DGP), Berlin,
2012. Plattform presentation.
Stomper J, Braun M, Vogel W, Scheble V, Fend F, Perner S.
Landscape of Chromosome Number Changes during Prostate Cancer
Progression.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Plattform presentation.
Goeke F, Franzen A, Menon R, Huss S, Boehm D, Vogel W, Bootz F,
Schroeck A, Perner S.
SOX2 amplification is a common event in sinunasal squamous cell and
undifferentiated carcinomas
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Poster presentation.
Goeke F, Franzen, Menon R, Kirsten R, Boehm D, Vogel W, Bootz F,
Schroeck A, Perner S.
FGFR1 amplification in metastatic squamous cell carcinoma of the head
and neck – a potential target for a rational therapy ?
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Poster presentation.
Goeke F, Franzen A, Menon R, Scheble V, Goltz D, Kirsten R, Boehm D,
Vogel W, Schroeck A, Perner S.
Rationale for treatment of metastatic squamous cell carcinoma of the lung
using FGFR1 Inhibitors
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Plattform presentation.
Braun M, Shaikhibrahim Z, Nikolov P, Boehm D, Scheble V, Menon R,
Fend F, Kristiansen G, Wernert N, Perner S.
Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5 and ELK-1 is a
clonal event during prostate cancer progression.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Poster presentation.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Boehm D, Scheble V, Dobi
A, Fend F, Wernert N, Kristiansen G, Perner S.
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer a comparative study of two monoclonal
antibodies.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Poster presentation.
Braun M, Stomper S, Boehm D, Vogel W, Scheble V, Wernert N,
Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.
Improved method of detecting the ERG gene rearrangement in prostate
cancer using combined dual-color chromogenic and silver in-situ
hybridization.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Vancouver, 2012. Plattform presentation.
Perner S.
FGFR1 Amplifikation in Plattenepithelkarzinomen der Lunge und der
oberen Atemwege.
Tagung der Rheinisch-Westfälischen Pathologen, Essen, 2012, Plattform
presentation.
Menon R, Deng M, Boehm D, Fend F, Boehm D, Biskup S, and Perner S.
Whole-exome sequencing identifies potential therapeutic targets for
castration-resistant prostate cancer
AACR Special Conference on Advances in Prostate Cancer Research,
Orlando, FL, 2012. Poster presentation.
Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Boehm D, Scheble V, Dobi
A, Fend F, Wernert N, Kristiansen G, Perner S.
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer – a comparative study of two monoclonal
antibodies.
Symposium der Arbeitsgruppe für urologische Forschung (AuF) der
Deutschen Gesellschaft für Urologie (DGU), Jena, 2011. P oster
presentation.
Braun M, Shaikhibrahim Z, Nikolov P, Boehm D, Scheble V, Menon R,
Fend F, Kristiansen G, Wernert N, Perner S.
Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5 and ELK-1 is a
clonal event during prostate cancer progression.
Symposium der Arbeitsgruppe für urologische Forschung (AuF) der
Deutschen Gesellschaft für Urologie (DGU), Jena, 2011. oster P
presentation.
Braun M, Stomper J, Boehm D, Vogel W, Scheble V, Wernert N,
Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.
Improved method of detecting the ERG gene rearrangement in prostate
cancer using combined dual-color chromogenic and silver in-situ
hybridization. Symposium der Arbeitsgruppe für urologische Forschung
(AuF) der Deutschen Gesellschaft für Urologie (DGU), Jena,
2011. P lattform presentation.
Braun M, Stomper J, Vogel W, Scheble V, Fend F, Perner S.
Landscape of Chromosome Number Changes during Prostate Cancer
Progression.
Symposium der Arbeitsgruppe für urologische Forschung (AuF) der
Deutschen Gesellschaft für Urologie (DGU), Jena, 2011. P oster
presentation.
Braun M, Kirsten R, Rupp N, Deng M, Moch H, Kristiansen G, Perner S.
Quantification of Protein Expression in Immunohistochemical Sections
using a newly launched Image Analysis Software.
Symposium der Arbeitsgruppe für urologische Forschung (AuF) der
Deutschen Gesellschaft für Urologie (DGU), Jena, 2011. P oster
presentation.
Braun M, Kirsten R, Rupp N, Deng M, Moch H, Kristiansen G, Perner S.
Quantification of Protein Expression in Immunohistochemical Sections
using a newly launched Image Analysis Software.
Pathology Visions Conference 2011 der Digital Pathology Association
(DPA), San Diego, 2011. Plattform presentation.
Menon R, Nikolov P, Braun M, Scheble V, Fend F, Boehm D, Biskup S,
Perner S.
Genome-wide Massively Parallel Sequencing using SOLiDTM 4 of formalin
fixed paraffin embedded prostate cancer tissue.
96. Jahrestagung der Deutschen Gesellschaft fur Pathologie (DGP),
Leipzig, 2011. Plattform presentation.
Menon R, Schwamborn K, Nikolov P, Braun M, Caprioli R, Perner S.
Determining the Protein Profile of Prostate Cancer Samples harboring the
ERG rearrangement using MALDI Imaging Mass Spectrometry.
Jahrestagung der Deutschen Gesellschaft fur Pathologie (DGP), Leipzig,
2011. Poster presentation.
Menon R, Scheble V, Scharf G, Nikolov P, Petersen K, Fend F, Reischl
M, Perner S.
NKX3.1, ERG and AR define genetic alteration patterns correlating with
tumor progression in prostate cancer.
Jahrestagung der Deutschen Gesellschaft fur Pathologie (DGP), Leipzig,
2011. Poster presentation.
Braun M, Maier S, Wilbertz T, Scheble V, Reischl M, Mikut R, Menon R,
Nikolov P, Petersen K, Beschorner C, Moch H, Kakies C, Protzel C,
Bauer J, Soltermann A, Fend F, Staebler A, Lengerke C, Perner S.
SOX2 amplification is a common event in squamous cell carcinomas of
different organ sites.
Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP), Leipzig,
2011. Poster presentation.
Braun M, Gakis G, Todenhöfer T, Fend F, Stenzl A, Perner S.
Lymphovascular Invasion is a Risk Factor for Understaging in pT1
Urothelial Carcinoma of the Bladder.
Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP), Leipzig,
2011. Poster presentation.
Braun M, Rupp N, Kirsten R, Deng M, Moch H, Kristiansen G, Perner S.
Manuscript in preparation.
Quantification of Protein Expression in Immunohistochemical Sections
using a newly launched Image Analysis Software.
Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP), Leipzig,
2011. Plattform presentation.
Scheble V, Scharf G, Menon R, Nikolov P, Petersen K, Fend F, Reischl
M, Perner S.
NKX3.1, ERG and AR define genetic alteration patterns correlating with
tumor progression im prostate cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Antonio, 2011. Poster presentation.
Braun M, Gakis G, Todenhöfer T, Fend F, Stenzl A, Perner S.
Lymphovascular invasion is a risk factor for understaging in pT1 urothelial
carcinoma of the bladder.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Antonio, 2011. Plattform presentation.
Braun M, Maier S, Wilbertz T, Scheble V, Reischl M, Mikut R, Menon R,
Nikolov P, Beschorner C, Moch H, Kakies C, Protzel C, Bauer J,
Soltermann A, Fend F, Staebler A, Lengerke C, Perner S.
SOX2 amplification is a common event in squamous cell carcinomas of
different organ sites.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Antonio, 2011. Plattform presentation.
Menon R, Schwamborn K, Nikolov P, Braun M, Caprioli R, Perner S.
Determining the protein profile of prostate cancer samples harboring the
ERG rearrangement using MALDI Imaging Mass Spectrometry. Kongress
der United States and Canadian Academy of Pathology (USCAP), San
Antonio, 2011. Plattform presentation.
Perner S.
Dangerous Liaisons im Prostatakarzinom – Klinische und biologische
Bedeutung rekurrenter Genfusionen im Prostatakarzinom.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Rudolf-Virchow-Award Lecture.
Stiedl, AC, Wagner PL, Wilbertz T, Altorki NK, Fend F, Moch H,
Soltermann A, Perner S.
KRAS Amplification in Non-Small Cell Lung Carcinoma.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Plattform presentation.
Braun M, Scheble V, Wilbertz T, Stiedl AC, Petersen K, Schilling D,
Kuefer R, Fend F, Kristiansen G, Rubin MA, Perner S.
Cohort design and localization is critical for the understanding of the
clinical implications of prostate cancer with ERG rearrangement.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Plattform presentation.
Braun M, Hennenlotter J, Schilling D, Petersen K, Scheble V, Fend F,
Perner S.
The HOPE® fixation technique – a promising alternative to common
biobanking approaches.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Poster presentation.
Wilbertz T, Wagner P, Stiedl AC, Petersen K, Scheble V, Altorki NK, Storz
M, Moch H, Weder W, Fend F, Soltermann A, Perner S.
SOX2 amplification is a frequent event in squamous cell lung cancer.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Plattform presentation.
Scheble V, Braun M, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl
M, Fend F, Kristiansen G, Rubin MA, Bubendorf L, Perner S.
ERG rearrangement is specific to prostate cancer and does not occur in
any other common epithelial tumour.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Plattform presentation.
Scheble V, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D, Seitz
G, Fend F, Kristiansen G, Perner S.
ERG rearrangement as a marker to differentiate between small cell lung
cancer and small cell prostate cancer.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Berlin, 2010.
Poster presentation.
Scheble V, Braun M, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl
M, Fend F, Kristiansen G, Bubendorf L, Rubin MA, Perner S.
ERG rearrangement is specific to prostate cancer and does not occur in
any other common epithelial tumour.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Washington, 2010. Plattform presentation.
Wilbertz T, Wagner PL, Stiedl AC, Petersen K, Scheble V, Moch H, Altorki
NK, Soltermann A, Perner S.
SOX2 amplification is a frequent event in squamous cell lung cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Washington, 2010. Poster presentation.
Braun M, Scheble V, Wilbertz T, Stiedl AC, Petersen K, Schilling D,
Kuefer R, Fend F, Kristiansen G, Rubin MA, Perner S.
Cohort design and localization is critical for the understanding of the
clinical implications of prostate cancer with ERG rearrangement.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Washington, 2010. Poster presentation.
Stiedl AC, Wagner PL, Wilbertz T, Fend F, Altorki NK, Perner S.
KRAS Amplification in Non-Small Cell Lung Carcinoma.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Washington, 2010. Poster presentation.
Scheble V, Braun M, Ruiz C, Petersen K, Fend F, Bubendorf L, Perner S.
ERG rearrangement is specific to prostate cancer and does not occur in
any other common epithelial tumor.
Symposium Urologische Forschung der Deutschen Gesellschaft für
Urologie, München, 2009. Plattform presentation.
Perner S, Pflüger D, Rickman DS, Sboner A, de la Taille A, Küfer R,
Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.
Defining the molecular subclass of ERG rearrangement prostate cancer
and identification of N-myc Downstream Regulated Gene 1 (NDRG1) as
ERG fusion partner.
Symposium Urologische Forschung der Deutschen Gesellschaft für
Urologie, München, 2009. Plattform presentation.
Scheble V, Braun M, Ruiz C, Petersen K, Fend F, Bubendorf L, Perner S.
ERG rearrangement is specific to prostate cancer and does not occur in
any other common epithelial tumor.
Tagung der Deutschen Gesellschaft für Urologie (DGU), Dresden, 2009.
Poster presentation.
Perner S, Pflüger D, Rickman DS, Sboner A, de la Taille A, Küfer R,
Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.
Defining the molecular subclass of ERG rearrangement prostate cancer
and identification of N-myc Downstream Regulated Gene 1 (NDRG1) as
ERG fusion partner.
Tagung der Deutschen Gesellschaft für Urologie (DGU), Dresden, 2009.
Poster presentation.
Perner S, Bass AJ, Watanabe H, Mermell CH, Yu S, Weir BA, LaFargue
CJ, Giordano TJ, Wagner PL, Rubin MA, Dahl O, Beer DG, Rustgi AK,
Meyerson M.
SOX2 als amplifiziertes Onkogen in Plattenepithelkarzinomen der Lunge
und des Ösophagus.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Freiburg, 2009.
Plattform presentation.
Perner S, Pflüger D, Rickman DS, LaFargue CJ, Svensson MA,
Demichelis F, Stephan C, Dietel M, Fritzsche FR, Han B, Palanisamy N,
Mehra R, Allory Y, Maille P, de la Taille A, Küfer R, Tewari AK,
Chinnaiyan AM, Rubin MA, Kristiansen G.
SLC45A3 is ein häufiger ETS-Fusionspartner im Prostatakarzinom.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Freiburg, 2009.
Plattform presentation.
Perner S, Svensson MA, Hossain R, Day J, Groskopf J, Hofer MD, Kuefer
R, Rickman DS, Rubin MA.
TMPRSS2-ERG Genfusion bestimmt das metastatische Verhalten beim
Prostatakarzinom.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Freiburg, 2009.
Plattform presentation.
Perner S, Wagner PL, Rickman DS, LaFargue CJ, Kitabayashi N,
Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA.
In-Situ-Nachweis der KRAS-Amplifikation und Assoziation mit erhöhter
p21-Expression in Nicht-kleinzelligen Lungenkarzinomen.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Freiburg, 2009.
Plattform presentation.
Schilling D, Hennenlotter J, Mittenzwei K, Scharpf M, Stenzl A, Perner S.
Die intraoperative digitale Palpation bei der Radikalen Prostatektomie hat
eine hohe Vorhersagekraft zur Detektion von Tumorarealen.
Jahrestagung der Südwestdeutschen Gesellschaft für Urologie
(SWDGU), Freiburg 2009. Poster presentation.
Perner S, Pflueger D, Rickman DS, CJ LaFargue, Svensson MA,
Demichelis F, Stephan C, Dietel M, Fritzsche FR, Han B, Palanisamy N,
Mehra R, Allory Y, Maille P, de la Taille A, Kuefer R, Tewari AK,
Chinnaiyan AM, Kristiansen G, Rubin MA.
SLC45A3 is a common ETS family fusion partner in prostate cancer.
Kongress der European Association of Urology (EAU), Stockholm 2009.
Poster presentation.
Perner S, Svensson MA, Hossain R, Day J, Groskopf J, Hofer MD, Kuefer
R, Rickman DS, Rubin MA.
TMPRSS2-ERG gene fusion defines a metastatic phenotype of prostate
cancer.
Kongress der European Association of Urology (EAU), Stockholm 2009.
Plattform presentation.
Perner S, Wagner PL, Soltermann A, LaFargue CJ, Tischler V, Weir BA,
Weder W, Meyerson M, Giordano TJ, Moch H, Rubin MA.
TTF1 expression in non-small cell lung carcinoma: association with TTF1
gene amplification and improved survival.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2009. Poster presentation.
Perner S, Pflueger D, Rickman DS, LaFargue CJ, Svensson MA,
Demichelis F, Stephan C, Dietel M, Fritzsche FR, Han B, Palanisamy N,
Mehra R, Allory Y, Maille P, de la Taille A, Kuefer R, Tewari AK,
Chinnaiyan AM, Kristiansen G, Rubin MA.
SLC45A3 is a common ETS family fusion partner in prostate cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2009. Plattform presentation.
Perner S, Svensson MA, Hossain R, Day J, Groskopf J, Hofer MD, Kuefer
R, Rickman DS, Rubin MA.
TMPRSS2-ERG gene fusion defines a metastatic phenotype of prostate
cancer.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Boston, 2009. Poster presentation.
Perner S, Demichelis F, Sboner A, Setlur S, Rubin MA.
TFF3 expression defines TMPRSS2-ERG fusion negative prostate
cancer.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Berlin, 2008.
Poster presentation.
Perner S, Demichelis F, Johnson L, Weir B, Barletta J, Meyerson M,
Chirieac L, Rubin MA.
TTF1 amplification defines TTF1 overexpression in lung
adenocarcinomas.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Berlin, 2008.
Poster presentation.
Perner S, Andren O, Fall K, Rubin MA.
Empiric evaluation of the AJCC TNM Staging System for T1a,b prostate
cancers.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Denver, 2008. Poster presentation.
Perner S, Demichelis F, Johnson L,. Weir B, Barletta J, Meyerson M,
Chirieac L, Rubin MA.
TTF1 amplification defines TTF1 overexpression in lung
adenocarcinomas.
Kongress der United States and Canadian Academy of Pathology
(USCAP) annual meeting, Denver, 2008. Poster presentation.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Bismar TA, Chinnaiyan
AM, Rubin MA.
Morphological features of TMPRSS2-ERG positive prostate cancer.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Magdeburg,
2007. Plattform presentation.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Chinnaiyan
AM, De Marzo AM, Rubin MA.
TMPRSS2-ERG fusion prostate cancer: an early molecular event
associated with invasion.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Magdeburg,
2007. Poster presentation.
Perner S, Demichelis F, Beroukhim R, Mosquera JM, Tomlins SA, Kuefer
R, Meyerson M, Lee C, Chinnaiyan AM, Rubin MA.
TMPRSS2-ERG fusion provides insight into the heterogeneity of prostate
cancer.
Tagung der Deutschen Gesellschaft für Pathologie (DGP) Magdeburg,
2007. Plattform presentation.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J,
Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
TMPRSS2-ERG fusion prostate cancer: an early molecular event
associated with invasion.
Kongress der United States and Canadian Academy of Pathology
(USCAP), San Diego, 2007. Poster presentation.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J,
Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
TMPRSS2-ERG fusion prostate cancer: an early molecular event
associated with invasion.
AACR International Conference „Frontiers in Cancer Prevention
Research“, Boston, 2006. Plattform presentation.
Perner S, Demichelis F, Beroukhim R, Mosquera JM, Tchinda J, Tomlins
SA, Setlur S, Hofer MD, Kuefer R, Fall K, Paris PL, DeMarzo AM, Sun
XW, Meyerson M, Lee C, Seller WR, Chinnaiyan AM, Rubin MA.
TMPRSS2-ERG fusion provides insight into the heterogeneity of prostate
cancer.
11th Prouts Neck Meeting on Prostate Cancer, Prouts Neck, ME, 2006.
Poster presentation.
Perner S, Demichelis F, Beroukhim R, Mosquera JM, Tchinda J, Tomlins
SA, Setlur S, Hofer MD, Kuefer R, Fall K, Paris PL, DeMarzo AM, Sun
XW, Meyerson M, Lee C, Seller WR, Chinnaiyan AM, Rubin MA.
TMPRSS2-ERG fusion provides insight into the heterogeneity of prostate
cancer.
BWH-BRI Cancer Center Retreat, Boston, 2006. Poster presentation.
Perner S, Demichelis F, Beroukhim R, Schmidt FH , Mosquera JM,
Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun
XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.
TMPRSS2-ERG fusion associated deletions provide insight into the
heterogeneity of prostate cancer.
Junior Investigators’ Health Disparities Research Poster Session,
Boston, 2006. Poster presentation.
Perner S, Hofer MD, Li H, Kuefer R, Gschwend J, Hautmann R, Möller P,
Rubin MA.
Prostate-Specific Membrane Antigen (PSMA) expression as a predictor of
prostate cancer progression.
Kongress der United States and Canadian Academy of Pathology
(USCAP), Atlanta, 2006. Poster presentation.
Perner S, Brüderlein S, Hasel C, Waibel I, Nielsen KV, Plesch A, Möller
P.
Quantifying telomere lengths of human individual chromosome arms by
centromere-calibrated flourescence-in-situ-hybridization and digital
imaging.
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Rostock, 2004.
Poster presentation.
Perner S, Brüderlein S, Hasel C, Waibel I, Nielsen KV, Plesch A, Möller
P.
Quantifying telomere lengths of human individual chromosome arms by
centromere-calibrated flourescence-in-situ-hybridization and digital
imaging.
Tagung der Bayrischen Pathologen, Würzburg, 2003. Plattform
presentation.
Perner S, Brüderlein S, Hasel C, Waibel I, Nielsen KV, Plesch A, Möller
P.
Quantifying telomere lengths of human individual chromosome arms by
centromere-calibrated flourescence-in-situ-hybridization and digital
imaging.
Tagung der Deutschen und Schweizer Bindegewebsgesellschaft, Ulm,
2003. Poster presentation.
Eingeladene Vorträge
Tumorgenomik als rationale Grundlage für die personalisierte Therapie –
Fünf Jahre Onkologisches Zentrum
Symposium am Marienhospital Stuttgart, Stuttgart, Juni 2015
Marburger Pathologie-Symposium über konventionelle und molekulare
Pathologie solider Tumoren: Strategie in Forschung und
Krankenversorgung im Jahr 2020, Marburg, Juni 2015
Planung eines wissenschaftlichen Auslandsaufenthalts und der Rückkehr
Tagung der Deutschen Gesellschaft für Pathologie (DGP), Frankfurt,
May/Juni 2015
Pathology and Biology of Prostate Cancer
Keynote Lecture at the Meeting of the Swedish Society of Pathology,
Örebro, Sweden, May 2015
Die Bedeutung der Mediator-Komplexuntereinheit MED15 in
Signalwegen des Hormon-refraktären Prostatakarzinoms
2. Interdisziplinäres Androgenrezeptor-Meeting Astellas,
Oberding/Notzing bei München, April 2015
Pathology and Prostate Cancer Therapy
Joint Meeting of the EAU Section of Uropathology (ESUP) and the EAU
Section of Urological Research (ESUR) im Rahmen des Kongresses der
European Association of Urology (EAU),
EAU Meeting, Madrid, March 21, 2015
Welche Informationen benötigen der Urologe und der therapieführende
Arzt aus pathologischer Sicht? Befundungsstandards, Arbeit eines
Referenzlabors, Grading- und Staginginstrumente, Symposium zur
Kooperation Urologie und Radiologie des Curagita Radiologienetzes,
Heidelberg, Okt. 2014
ERG Rearrangement im Prostatakarzinom
Astellas 1. Interdisziplinäres Androgenrezeptor Meeting, Ulm April 2014
Translational Lung Cancer Research
Gastseminar Hämatologie, Universitätsspital Basel, Febr. 2014
ALK-Diagnostik mittels Immunhistochemie und FISH
5th Novartis Research Days, Nürnberg, Nov. 2013
Welche Informationen benötigen der Urologe und der therapieführende
Arzt aus pathologischer Sicht? Befundungsstandards, Arbeit eines
Referenzlabors, Grading- und Staginginstrumente, Symposium zur
Kooperation Urologie und Radiologie des Curagita Radiologienetzes,
Heidelberg, Nov. 2013
First results from next-generation sequencing efforts in prostate cancer
research
Joint Annual Meeting of the Swiss and Austrian Society of Pathology,
Baden, CH, Nov. 2013
PSMA-Expression beim Prostatakarzinom
Symposium zum PSMA-Targeting beim Prostatakarzinom
Klinik für Nuklearmedizin, Universitätsklinikum Ulm, Sept. 2013
Novel Biomarkers and Targets in Primary and Metastatic Prostate
Cancer
Seminar Series of the SFB 824 „Imaging for Selection, Monitoring and
Individualization of Cancer Therapies“, TU München, Sept. 2013
Pathophysiologie und Histologie des Prostatakarzinoms
Symposium zur Kooperation Urologie und Radiologie des Curagita
Radiologienetzes, Heidelberg, Juli 2013
Translational Lung Cancer Research
Symposium Series, Karlsruhe Institute of Technology, Karlsruhe, June
2013
Translational Lung Cancer Research
Symposium Series of the University of Colorado Anschutz Medical
Campus and Cancer Center, Aurora, CO, June 2013
Welche Informationen benötigen der Urologe und der therapieführende
Arzt aus pathologischer Sicht? Befundungsstandards, Arbeit eines
Referenzlabors, Grading- und Staginginstrumente
Symposium zur Kooperation Urologie und Radiologie des Curagita
Radiologienetzes, Heidelberg, April 2013
Molekulare Veränderungen beim Nierenzellkarzinom
Forum des Center of Integrated Oncology (CIO) Köln/Bonn zum Thema
Urologische Tumoren, Bonn, März 2013
Die Rolle des Pathologen als Entscheidungsträger
in klinischen Studien
Novartis Workshop, Köln, March 2013

TMPRSS2-ERG as a Prognostic Biomarker in Prostate Cancer
Consensus Conference of the International Society of Cancer Prevention
(ISCaP), European Association of Urology (EAU) Congress, Milan,
March 2013
Non Small-Cell Lung Cancer Pathology, Molecular Subtypes and Testing
Novartis Region Europe Lung Cancer/LDK378 Cross Functional Training
Meeting, Milan, Febr. 2013

Prostatapathologie (G. Kristiansen , S. Perner)
Frühjahrssymposion der Deutschen Abteilung der Interantionalen
Akademie für Pathologie (IAP), Bonn, Febr. 2013
Pathophysiologie und Histologie des Prostatakarzinoms
Symposium zur Kooperation Urologie und Radiologie des Curagita
Radiologienetzes, Heidelberg, Febr. 2013
HNO und Pathologie- Symposium zur interdisziplinären Kooperation
zwischen HNO und Nachbarfächern
Bonn, Dez. 2012
From Translational Lung Cancer Research to Translational Research of
other Organs Sites
Wissenschaftliches Seminar, Pathologisches Institut, Universitätsklinikum
Heidelberg, Dez. 2012
Molekulare Diagnostik des Lungenkarzinoms – aktuelle Entwicklungen
Herbsttagung der Arbeitsgemeinschaft Pneumopathologie der Deutschen
Gesellschaft für Pathologie (DGP), Bremen Nov. 2012
BRAF Mutationstestung beim malignen Melanom
Workshop, 20. Jahrestagung der Arbeitsgemeinschaft Dermatologische
Histologie (ADH), Bonn Okt. 2012
FGFR1 in squamous cell cancers
24th European Congress of Pathology, Prague Sept. 2012
Genetische Alterationen des Prostatakarzinoms
Lunchseminar des Zentrums für Pathologie, Forensik und Genetik der
Medizinischen Hochschule Hannover, Juli 2012
Translationale Forschung und Diagnostik – Lunge
96. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP),
Berlin May/Juni 2012
Whole Exome Sequencing Identifies Potential Therapeutic Targets For
ERG non-rearranged Castration Resistant Prostate Cancer (CR-PCa)
Scientific Advisory Board Meeting of the CIO Cologne/Bonn, May 2012
What can we learn from molecular lung cancer research?
International Symposium of the SFB 832 (Tumor Microenvironment)
Bad Neuenahr, May 2012
Clinical Relevance of Gene Fusions in Prostate Cancer
30. Deutscher Krebskongress, Berlin, Febr. 2012
Konventionelles und molekulares Grading des Prostatakarzinoms
30. Deutscher Krebskongress, Berlin, Febr. 2012
Recurrent Gene Fusions in Prostate Cancer
EAU/DGU Symposium on Early Prostate Cancer – Novel Detection
Tools, Düsseldorf, Oct. 2011
Gene Alterations in Prostate and Lung Cancer
Guest Speaker at the Retreat of the SFB 832, Krakow, Sept. 2011
Recurrent Gene Fusions in Prostate Cancer – Clinical and Biological
Implications
Roche Nordic User Days, Helsinki, Sept. 2011
The impact of gene fusions with a focus on solid tumors
5. Mildrid-Scheel Cancer Conference
Königswinter, Jul 2011
Vorläuferläsionen des Prostatakarzinoms
Tagung der Deutschen Gesellschaft für Pathologie (DGP)
Leipzig, Jun 2011
Translationale Tumorforschung am Beispiel des Lungen- und
Prostatakarzinoms
Symposium zur Zukunft der akademischen Pathologie in Deutschland
Universitätsklinikum Göttingen, Juni 2011
Biomarker bei der Prognose von Prostatakrebs
Roche Tage, Mannheim Juni 2011
Dangerous Liaisons im Prostatakarzinom – Klinische und biologische
Bedeutung rekurrenter Genfusionen im Prostatakarzinom
Wissenschaftsseminar, Klinik für Urologie, Universitätsklinikum Ulm, Mai
2011
Molekularpathologie der Prostata – Was ist für die tägliche Diagnostik
relevant und einsetzbar?
13. Bamberger Morphologietage, Bamberg, Jan. 2011
Clinical implications of recurrent gene fusions in prostate cancer
Wissenschaftsseminar des Instituts für Pathologie, Universitätsklinikum
Frankfurt, Nov. 2010
Clinical implications of recurrent gene fusions in prostate cancer
Workshop “Novel Tools for Early Detection of Prostate Cancer” der
Deutschen Krebshilfe, Bonn, Okt. 2010
Recurrent gene fusions in prostate cancer
First Comprehensive Cancer Research Training Program in Medical
Oncology (CCRTP-MO) by the University Hosptials of Tuebingen and
Freiburg, Hinterzarten, Sept. 2010
Clinical implications of gene fusions in prostate cancer
Intercongress Meeting, European Society of Pathology, Krakau, Sept
2010
Dangerous Liaisons im Prostatakarzinom – Klinische und biologische
Bedeutung rekurrenter Genfusionen im Prostatakarzinom
8. Abbot FISH-Workshop (FISH in der Tumordiagnostik), Bern, Aug.
2010
Dangerous Liaisons im Prostatakarzinom – Klinische und biologische
Bedeutung rekurrenter Genfusionen im Prostatakarzinom
Uro-Onkologischer Arbeitskreis Tübingen, Tübingen, Juli 2010
Clinical implications of gene fusions in prostate cancer
Ventana Symposium, Tuscon, AZ, März 2010
Gibt es Grundlagen für eine fokale Therapie des Prostatakarzinoms
Heinrich-Warner Symposium, Hamburg, Febr. 2010
Molekulare und genetische Veränderungen des Prostatakarzinoms
Veranstaltung “Aktuelles über das Prostatakarzinom” des Tübinger
Prostatakrebszentrums, Tübingen, Febr. 2010
Dangerous Liaisons im Prostatakarzinom – Klinische und biologische
Bedeutung rekurrenter Genfusionen im Prostatakarzinom
Friday-Lunch Seminar, Helmholtzzentrum für Infektionsforschunge,
Braunschweig, Jan. 2010
Dangerous Liaisons im Prostatakarzinom – Klinische und biologische
Bedeutung rekurrenter Genfusionen im Prostatakarzinom
Symposium Urologische Forschung der Deutschen Gesellschaft für
Urologie, München, 2009
Bedeutung von chromosomalen Rearrangements beim Prostatakarzinom
Symposium Translationale Krebsforschung Heidelberg – Tübingen,
Stuttgart, Juli 2009
Die Entschlüsselung des Lungenkarzinom-Genoms als Basis für einen
translationalen Forschungsansatz
Wissenschaftliches Kolloquium des Instituts für Pathologie,
Universitätsspital Zürich, Mai 2009
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Forschungskolloquium des Instituts für Pathologie, Universitätsklinikum
Bonn, Febr. 2009
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Forschungskolloquium der Klinik für Urologie, Universitätsklinikum des
Saarlandes, Homburg, Jan. 2009
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Forschungskolloquium des Instituts für Pathologie, Universitätsspital
Basel, Jan. 2009
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Workshop des Deutschen Prostatakarzinom-Konsortiums,
Vierzehnheiligen, Nov. 2008
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Forschungskolloquium des Max-Planck-Instituts für Neurologische
Forschung Köln, Mai 2008
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Wissenschaftliches Kolloquium des Instituts für Pathologie,
Universitätsklinikum Düsseldorf, März 2008
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Wissenschaftliches Kolloquium des Instituts für Pathologie, Klinikum der
RWTH Aachen, März 2008
Die klinische und biologische Bedeutung des Prostatakarzinoms mit
Genfusion
Wissenschaftliches Kolloquium des Instituts für Pathologie,
Universitätsklinikum Tübingen, März 2008
Patente und Erfindungen
Co-Investigator des Patents: Chromosomal Rearrangements in the
Prognosis of Epithelial Cell Cancers (US Patent No. 11/519.397; EU Patent
No. 13159513.4-1404).
Lead-Investigator des Patents: MED15 and MED12 as a diagnostic,
predictive and prognostic biomarker as well as therapeutic targets in
castration-resistant prostate cancer (EU Patent No. 13180632.5).
Stand: August 2015